Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain

European Journal of Pharmacology

Volumn 573, Issue 1-3, 2007, Pages 93-99

  Hirose, Ryo ^a   Manabe, Haruhiko ^a   Nonaka, Hiromi ^a   Yanagawa, Koji ^a   Akuta, Kaori ^a   Sato, Soichiro ^a   Ohshima, Etsuo ^a   Ichimura, Michio ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

(Suncus murinus); Emesis; High affinity rolipram binding site; Phosphodiesterase 4 inhibitors

Indexed keywords

4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; DENBUFYLLINE; KF 19514; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; EX VIVO STUDY; IN VIVO STUDY; INSECTIVORE; MALE; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; RAT; SUNCUS MURINUS; VOMITING;

ANIMALS; BENZAMIDES; BINDING SITES; BINDING, COMPETITIVE; BRAIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; KINETICS; MALE; MOLECULAR STRUCTURE; NAPHTHYRIDINES; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; SHREWS; TRITIUM; VOMITING; XANTHINES;

EID: 34648844239     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.045     Document Type: Article

References (32)

1. Aoki M., Kobayashi M., Ishikawa J., Saita Y., Terai Y., Takayama K., Miyata K., and Yamada Y. A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J. Pharmacol. Exp. Ther. 295 (2000) 255-260
2. Aoki M., Fukunaga M., Sugimoto T., Hirano Y., Kobayashi M., Honda K., and Yamada T. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J. Pharmacol. Exp. Ther. 298 (2001) 1142-1149
3. Barnette M.S. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 53 (1999) 193-229
4. Carpenter D.O., Briggs D.B., Knox A.P., and Strominger N. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J. Neurophysiol. 59 (1988) 358-369
5. Chen Y., Saito H., and Matsuki N. Ethanol-induced emesis in the house musk shrew, Suncus murinus. Life Sci. 60 (1997) 253-261
6. i) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
7. Colbert E.H. Evolution of the vertebrates (1958), John Wiley and Sons, Inc., New York 249-261
8. Dent G., and Giembycz M.A. Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother. 3 (1995) 423-437
9. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39 (1996) 120-125
10. Gardner C.J., Twissell D.J., Dale T.J., Gale J.D., Jordan C.C., Kilpatrick G.J., Bountra C., and Ward P. The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br. J. Pharmacol. 116 (1995) 3158-3163
11. Giembycz M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr. Opin. Pharmacol. 5 (2005) 238-244
12. Heaslip R.J., and Evans D.Y. Emetic, central nervous system and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 286 (1995) 281-290
13. Hebenstreit G.F., Fellerer K., Fichte K., Fischer G., Geyer N., Meya U., Sastre-Y-Hernández M., Schöny W., Schratzer M., Soukop W., Trampitsch E., Varosanec S., Zawada E., and Zöchling R. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22 (1989) 156-160
14. Hughes B., Howat D., Lisle H., Holbrook M., James T., Gozzard N., Blease K., Hughes P., Kingaby R., Warrellow G., Alexander R., Head J., Boyd E., Eaton M., Perry M., Wales M., Smith B., Owens R., Catterall C., Lumb S., Russell A., Allen R., Merriman M., Bloxham D., and Higs G. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol. 118 (1996) 1183-1191
15. Hughes P., Owens R., Perry M., Warrellow G., and Allen R. PDE4 inhibitors: the use of molecular cloning in the design and development of novel drugs. Drug Discov. Today 2 (1997) 89-101
16. Ito C., Isobe Y., Kijima H., Kiuchi Y., Ohtsuki H., Kawamura R., Tsuchida K., and Higuchi S. The anti-emetic activity of GK-128 in Suncus murinus. Eur. J. Pharmacol. 285 (1995) 37-43
17. Kincaid R.L., and Manganiello V.C. Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrate. Method. Enzymol. 159 (1988) 457-470
18. Laliberte F., Han Y., Govindarajan A., Giroux A., Liu S., Bobechko B., Lario P., Bartlett A., Gorseth E., Gresser M., and Huang Z. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39 (2000) 6449-6458
19. Manabe H., Akuta K., Sejimo H., Kawasaki H., Nukui E., Ichimura M., Kase H., Kawakita T., Suzuki F., Kitamura S., Sato S., and Ohmori K. Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. Eur. J. Pharmacol. 332 (1997) 97-107
20. Munson P.J., and Rodbard P. Ligand, a versatile computerized approach for characterization of ligand-binding system. Anal. Biochem. 107 (1980) 220-239
21. 3H]rolipram binding autoradiography: comparison with monkey and rat brain. J. Chem. Neuroanat. 20 (2000) 349-374
22. Raeburn D., Underwood S.L., Lewis S.A., Woodman V.R., Battram C.H., Tomkinson A., Sharma S., Jordan R., Souness J.E., Webber S.E., and Karlsson J.-A. Anti-inflammatory and bronchodilator properties of RP73401, a novel and selective phosphodiesterase type 4 inhibitor. Br. J. Pharmacol. 113 (1994) 1423-1431
23. Robichaud A., Tattersall F.D., Choudhury I., and Rodger I.W. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 38 (1999) 289-297
24. Robichaud A., Stamatiou P.B., Catherine Jin S.-L., Lachance N., Macdonald D., Laliberte F., Liu S., Huang Z., Conti M., and Chan C.-C. Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110 (2002) 1045-1052
25. Rocque W.J., Tian G., Wiseman J.S., Holmes W.D., Zajac-Thompson I., Willard D.H., Patel I.R., Wisely G.B., Clay W.C., Kadwell S.H., Hoffman C.R., and Luther M.A. Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 36 (1997) 14250-14261
26. Sawanishi H., Suzuki H., Yamamoto S., Waki Y., Kasugai S., Ohya K., Suzuki N., Miyamoto K., and Takagi K. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines. J. Med. Chem. 40 (1997) 3248-3253
27. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127 (1986) 105-115
28. Souness J.E., and Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell. Signal. 9 (1997) 227-236
29. Torphy T.J., and Cieslinski L.B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 37 (1990) 206-214
30. Torphy T.J., and Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46 (1991) 512-523
31. Ueno S., Matsuki N., and Saito H. Suncus murinus: a new experimental model in emesis research. Life Sci. 41 (1987) 513-518
32. Ueno S., Matsuki N., and Saito H. Suncus murinus as a new experimental model for motion sickness. Life Sci. 43 (1988) 413-420